Humira Sales Down 25% as AbbVie Cuts Two Programs

[{"selector":"#anim-2f966daa-3922-4720-80d6-6940a4e17ed2","keyframes":{"opacity":[0,1]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-a7bbca32-ffa0-4ebe-a71c-33da985daa8d","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

1. AbbVie's Humira sales have fallen by more than 25% due to the introduction of biosimilars.

[{"selector":"#anim-fc3a8d48-ee57-4213-b097-032c5e2f2760","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

2. The first Humira biosimilar, Amgen's Amjevita, hit the U.S. market on January 31, 2023.

[{"selector":"#anim-2f01d383-6275-4689-969a-7fbac5b76b81","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

3. Despite the decline, AbbVie is managing the situation well, according to outgoing CEO Rick Gonzalez.

[{"selector":"#anim-6a713ce6-6273-4b4b-8c44-de6456ce4c6e","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

4. Eight other biosimilars have been approved by the FDA, and two more are currently under review.

[{"selector":"#anim-262cbfaa-f6fb-4127-8945-6c6b5231ce02","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-4af0cdda-0548-494e-9eaf-7f2a3f913563","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 5. AbbVie is focusing on its other immunology drugs, Rinvoq and Skyrizi, which are expected to generate over $27 billion in annual revenue by 2027. Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-93bd0133-9fc2-4981-913d-cc232726547a","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 6. Rinvoq and Skyrizi missed revenue estimates by $127 million in the first quarter but are on track to contribute over $11 billion in combined sales this year. Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-6ca54696-f023-4dda-b7c3-26a5fd349f7d","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 7. Botox sales exceeded Wall Street estimates, with cosmetic applications surpassing $659 million, and therapeutic use increasing 17% to $719 million. Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-ea7cf99a-7ce1-4176-9849-a820f2cf51b4","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 8. AbbVie has announced the discontinuation of two early-stage pipeline programs: one for cystic fibrosis and the other for polymyalgia rheumatica and Crohn's disease. Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-7a914825-7c6b-403d-8c15-eb7d156ca3a8","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 9. Skyrizi is already approved to treat Crohn’s disease, and Rinvoq, the first oral Janus kinase (JAK) inhibitor for Crohn’s, is awaiting U.S. approval after being greenlit in the EU. Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-4f5799c8-74f7-4bac-83d5-094c2fc0041b","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 10. After leading the company for ten years, CEO Rick Gonzalez plans to step down following the transition for Humira biosimilars, potentially taking on the role of executive chairman during the transition period. Gray Frame Corner Gray Frame Corner

Swipe up for more BIOMARKER news!

[{"selector":"#anim-94d5a803-6dfe-49c2-b2db-7ef056e53946","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Learn more